Department of Pathophysiology, College of Basic Medical Sciences, Chongqing Medical University, Chong-qing, China.
Eur Rev Med Pharmacol Sci. 2024 Feb;28(3):862. doi: 10.26355/eurrev_202402_35365.
The article "MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer's disease", by D.-Y. Liu and L. Zhang, published in Eur Rev Med Pharmacol Sci 2019; 23 (19): 8523-8532-DOI: 10.26355/eurrev_201910_19166-PMID: 31646584 has been retracted by the Editor in Chief. A 2020 investigation by a third party evidenced doubts about the originality of the Western blot figures, which share a similar background, regularly spaced bands, and rounded edges as a set of published papers. A report published by China's Ministry of Science and Technology in 2022 affirmed that upon investigation, it was discovered that instances of proxy investment were present in this paper. The Editor in Chief mistrusts the results and decided, therefore, to withdraw the manuscript for malpractice. The corresponding authors did not respond to journal correspondence about the retraction of this article. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/19166.
“MicroRNA-132 通过靶向阿尔茨海默病中的 GTDC-1 促进神经元细胞凋亡和激活 Tau 磷酸化”，刘 D.-Y. 和张 L. 发表于 Eur Rev Med Pharmacol Sci 2019; 23 (19): 8523-8532-DOI: 10.26355/eurrev_201910_19166-PMID: 31646584 的文章被主编撤回。2020 年第三方的一项调查对 Western blot 图的原创性产生了怀疑，这些图共享相似的背景、定期间隔的条带和圆形边缘，作为一组已发表的论文。中国科学技术部 2022 年发布的一份报告肯定了在调查中发现这篇论文存在代理投资的情况。主编对结果表示怀疑，并因此决定撤回该论文以处理不当行为。通讯作者未回复本刊对此文章撤回的意见。出版商对由此造成的任何不便表示歉意。https://www.europeanreview.org/article/19166.
